MediFind
Condition

Epidermolysis Bullosa

Symptoms, Doctors, Treatments, Research & More

Latest Research

Latest Advance
Study
  • Condition: Dystrophic Epidermolysis Bullosa with Pleural Effusion and Dilated Cardiomyopathy
  • Journal: JPMA. The Journal of the Pakistan Medical Association
  • Treatment Used: Symptomatic Treatment
  • Number of Patients: 1
  • Published —
This case report describes a patient with dystrophic epidermolysis bullosa that developed pleural effusion and dilated cardiomyopathy.
Latest Advance
Study
  • Condition: Junctional Epidermolysis Bullosa (GS-JEB) Patients with Nonsense Mutations
  • Journal: Molecular therapy : the journal of the American Society of Gene Therapy
  • Treatment Used: Gentamicin
  • Number of Patients: 0
  • Published —
This study examined if 0.5% gentamicin topical ointment could create new laminin 332 in generalized severe junctional epidermolysis bullosa (blistering disease; GS-JEB) skin wounds.
Latest Advance
Study
  • Condition: Junctional Epidermolysis Bullosa (JEB)
  • Journal: Expert opinion on biological therapy
  • Treatment Used: Emerging Drug, Cell, and Gene Therapies
  • Number of Patients: 0
  • Published —
This article discusses emerging drug, cell, and gene therapies for junctional epidermolysis bullosa (rare genetic blistering disorder; JEB).
Latest Advance
Study
  • Condition: Epidermolysis Bullosa (EB)
  • Journal: Journal of wound care
  • Treatment Used: Biocellulose, Carboxymethyl Cellulose, and Normal Saline Dressing
  • Number of Patients: 4
  • Published —
This study evaluated the effectiveness of a biocellulose, a carboxymethyl cellulose, and a normal saline wound dressing in the wound care management of epidermolysis bullosa (genetic skin blistering; EB) skin wounds.
Latest Advance
Study
  • Condition: Recessive Dystrophic Epidermolysis Bullosa
  • Journal: JCI insight
  • Treatment Used: Gene-Corrected Autologous Cell Therapy
  • Number of Patients: 0
  • Published —
This study tested the safety and efficacy of using gene-corrected autologous cell therapy to treat patients with recessive dystrophic epidermolysis bullosa.
Latest Advance
Study
  • Condition: Chronic itch with epidermolysis bullosa
  • Journal: Journal of the American Academy of Dermatology
  • Treatment Used: Neurokinin-1 receptor antagonist
  • Number of Patients: 14
  • Published —
The study researched the use of neurokinin-1 receptor antagonist in treating chronic itch in patients with epidermolysis bullosa.
Latest Advance
Study
  • Condition: Recessive Dystrophic Epidermolysis Bulbosa
  • Journal: JCI insight
  • Treatment Used: Lentiviral Fibroblast Gene Therapy
  • Number of Patients: 4
  • Published —
This study tested the safety and efficacy of using a lentiviral fibroblast gene therapy to treat patients with recessive dystrophic epidermolysis bulbosa.
Latest Advance
Study
  • Condition: Epidermolysis bullosa simplex
  • Journal: Orphanet journal of rare diseases
  • Treatment Used: Topically applied diacerein
  • Number of Patients: 0
  • Published —
This study evaluated the effects of topically applied diacerein in pediatric patients with generalized severe epidermolysis bullosa simplex.
Latest Advance
Study
  • Condition: Epidermolysis Bullosa (EB)
  • Journal: Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • Treatment Used: Surgery
  • Number of Patients: 46
  • Published —
This study investigated postoperative wound and scar healing outcomes in patients with epidermolysis bullosa (genetic skin condition; EB).
Latest Advance
Study
  • Condition: Recalcitrant Pemphigoid Diseases
  • Journal: Frontiers in immunology
  • Treatment Used: Rituximab (RTX)
  • Number of Patients: 28
  • Published —
This study assessed the effectiveness and safety of rituximab (RTX) in pemphigoid (immune) diseases.
Latest Advance
Study
  • Condition: Epidermolysis bullosa simplex (EBS)
  • Journal: Journal of the American Academy of Dermatology
  • Treatment Used: 1% diacerein cream
  • Number of Patients: 17
  • Published —
The study researched the effects of 1% diacerein cream in patients with epidermolysis bullosa simplex (EBS).